Medivir is a pharmaceutical company focusing on the development and commercialization of innovative treatments for cancer.
Medivir focuses on cancers of high unmet medical need to provide benefit to patients who so far have had few treatment options.Our projects >
Medivir leverages collaborations with academic and industrial partners in order to bring specialty knowledge, experience and other capabilities to our projects.Partnership >
Medivir´s phase II study of MIV-711 in patients with osteoarthritis published in Annals of Internal MedicineRead more
Investigator-initiated phase II clinical study of remetinostat started in patients with squamous cell carcinomaRead more
Futility analysis performed of the phase II combination study with birinapant and Keytruda® in colorectal cancer patientsRead more
Partnering is an important element of our business strategy. Together with our partners we have been successful in taking two products from research, through clinical development to launch on a global scale.